|
|
|
|
||
Update on SRPT:Sarepta Therapeutics follow up: possibly ticking lower on safety data for GSK's drisapersen (39.22 +0.37) GlaxoSmithKline is giving a presentation of its 48 week data for drisapersen for the treatment of Duchenne muscular dystrophy. See the April 9 15:15 comment under SRPT ticker for details on GSK's results. Biotech blogger Adam Feuerstien posted pictures of the safety data for drisapersen, which showed that 14 out of 18 patients in the continuous treatment arm experienced an injection site reaction, and 13 out of 18 patients experienced renal toxicity. This compared to 6 out of 18 and 7 out of 18 patients on placebo experiencing the same reactions. While these numbers sound high, it should be noted that no adverse events lead to withdrawal from the study in any treatment group. Additional, there was only one serious adverse event in the treatment group versus two serious adverse events in the placebo group. Tweet from AF, this guy should be watched closely by the SEC IMO: https://twitter.com/adamfeuerstein/status/322425667767660544/photo/1 Sarepta's safety profile has been clean thus far. In reporting 74 week results the company said, "Through 74 weeks, eteplirsen was well tolerated and there were no clinically significant treatment-related adverse events, serious adverse events, hospitalizations or discontinuations." Liver stuff doesn't scare me too much......but kidney stuff does(stuff, it's a technical term). t |
return to message board, top of board |